Precigen Announces FDA Approval of PAPZIMEOS, the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
On Aug. 15, 2025, Precigen announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS™ (zopapogene imadenovec-drba)…